Evidence map›Paper›PMID 39833534›Full record

ArticleArchives of dermatological research2025

Dual-center retrospective cohort analysis of high-risk cutaneous squamous cell carcinoma tumors.

Brandon Calley, Kendall Trieglaff, Nicole Boswell, Alan Vu, Sabrina Popatia, Daniel Benitez Rivera, Ulrich Kemmo Tsafack, Anjishnu Banerjee, Olushola Akinshemoyin Vaughn, Melanie A Clark

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Brandon CalleyDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Kendall TrieglaffDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Nicole BoswellDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Alan VuDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Sabrina PopatiaDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Daniel Benitez RiveraDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Ulrich Kemmo TsafackDepartment of Biostatistics, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Anjishnu BanerjeeDepartment of Biostatistics, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Olushola Akinshemoyin VaughnDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA.
Melanie A ClarkDepartment of Dermatology, Medical College of Wisconsin, 8701 W. Watertown Plank Road, Milwaukee, WI, 53226, USA. mclark@mcw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-risk cutaneous squamous cell carcinoma (hr-cSCC) tumors exhibit aggressive behavior, leading to local recurrence, metastasis, and mortality. The management of hr-cSCC tumors is not well-defined. To clarify the impact of clinical risk factors and management strategies on disease-related outcomes (DROs) in patients with hr-cSCCs. This dual-center retrospective cohort study reviewed patient records from 2007 to 2023, focusing on hr-cSCC tumors classified as high-risk according to two staging systems. 160 adult patients with hr-cSCC were included. Tumors > 2 cm were associated with a higher risk of recurrence, metastasis, and mortality, with greater risk for tumors > 4 cm. Nonsurgical therapies were linked to higher recurrence and mortality rates compared to surgical monotherapy. Patients whose initial treatment was delayed > 60 days following biopsy had increased incidence of DROs. Other variables associated with at least one DRO included female sex, higher tumor grade, lymphovascular invasion, and advanced AJCC-8 stages. Limitations of this study include its retrospective design, narrow demographics, and variable follow-up times. This study identifies increased tumor diameter, non-surgical treatments, delayed treatment > 60 days after biopsy, female sex, tumor grade, lymphovascular invasion, and advanced tumor stage as significant risk factors for DROs in hr-cSCC. Importantly, our study provides new clarifying evidence that delayed surgical treatment of hr-cSCCs > 60 days after biopsy is associated with elevated incidence of DROs.

Indexed as

Carcinoma, Squamous CellNeoplasm Recurrence, LocalSkin NeoplasmsAdultAgedAged, 80 and overBiopsyFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingRetrospective StudiesRisk FactorsCutaneous squamous cell carcinomaDistant recurrenceImaging surveillanceLocal recurrenceNodal metastasisRadiationSentinel lymph node biopsy

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.